Literature DB >> 15120711

The prostacyclin analogue beraprost sodium prevents development of arterial stiffness in elderly patients with cerebral infarction.

Tomohiro Nakayama1, Takashi Hironaga, Hatsue Ishima, Takashi Maruyama, Yuichi Masubuchi, Shinichiro Kokubun.   

Abstract

Prostacyclin (PGI(2)) inhibits platelet aggregation, smooth muscle cell proliferation, and vasoconstriction. Arterial stiffness assessed by pulse wave velocity (PWV) predicts mortality in various cardiovascular diseases. To study the preventive effects of a prostacyclin analogue, beraprost sodium, on arterial PWV values in elderly patients with cerebral infarction. Forty-four patients with a history of cerebral infarction received beraprost sodium (120 microg/day p.o.) or no beraprost sodium (control) for 3 months. Arterial PWV and ankle brachial indices (ABI) were determined prior to starting the medication and after 3 months of medication. Initially, there were no differences in age, blood pressure, and body mass index. Further, PWV or ABI did not differ between the beraprost sodium group (n = 22) and the control group (n = 22). After 3 months, PWV in beraprost sodium group was significantly reduced (-123 +/- 282) when compared with the control group (147 +/- 274)(P = 0.006). ABI was not significantly different when comparing the two groups at 3 months. Long-term administration of beraprost sodium prevents the decline in arterial biomechanics in elderly patients with cerebral infarction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120711     DOI: 10.1016/j.plefa.2003.10.004

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  5 in total

Review 1.  Arterial compliance and endothelial function.

Authors:  Marcelo L G Correia; William G Haynes
Journal:  Curr Diab Rep       Date:  2007-08       Impact factor: 5.430

2.  Combination therapy with beraprost sodium and aspirin for acute ischemic stroke: a single-center retrospective study.

Authors:  Xiao-Pu Chen; Dun-Can Wei; Qian Zhang; Si-Qia Chen; Wen-Zhen He
Journal:  J Int Med Res       Date:  2019-05-30       Impact factor: 1.671

3.  Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy.

Authors:  Ki Young Na; Dong Ki Kim; Sung Gyun Kim; Young-Ki Lee; Chun Soo Lim
Journal:  Trials       Date:  2013-09-02       Impact factor: 2.279

4.  Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke.

Authors:  Siqia Chen; Sisi Xie; Wenzhen He; Duncan Wei; Shunxian Li; Wenjie Chen
Journal:  Med Sci Monit       Date:  2017-09-12

5.  Short-Term Effects of Beraprost Sodium on the Markers for Cardiovascular Risk Prediction in Type 2 Diabetic Patients with Microalbuminuria.

Authors:  Yun Mi Choi; Hyuk Sang Kwon; Kyung Mook Choi; Won Young Lee; Eun Gyoung Hong
Journal:  Endocrinol Metab (Seoul)       Date:  2019-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.